Melky Cabrera Switches To The Legacy Agency

Blue Jays outfielder Melky Cabrera has changed agents, moving from ACES to The Legacy Agency, reports Liz Mullen of Sports Business Journal (via Twitter). He will be represented by Peter and Ed Greenberg, along with Chris Leible.

Cabrera is already under contract for 2014, the second year of his free agent deal with Toronto. He will make $8MM as he looks to bounce back from a disappointing 2013 campaign in which he saw just 372 pate appearances and posted a .279/.322/.360 slash line. Cabrera is set to hit free agency before the 2015 season at age thirty.

Red Sox Non-Tender Andrew Bailey

The Red Sox have declined to offer arbitration to right-handed reliever Andrew Bailey, the club announced (via a tweet from Mike Salk of WEEI.com). The 29-year-old will now hit the open market. He is represented by Jim Murray of Excel Sports Management.

Last year, Bailey threw 28 2/3 innings for the Sox, notching a 3.77 ERA and posting a strong 12.2 K/9 against 3.8 BB/9. His season ended after he suffered a shoulder injury, however, which ultimately required surgery. Bailey was a major part of the deal that sent Josh Reddick to the Athletics before the 2012 season.

We had heard yesterday that Boston would tender a contract to Bailey, but that obviously did not occur. As noted in that post, Bailey is expected to miss a significant portion of 2014, though he says his rehab is progressing well.

Yankees Will Not Offer Over $200MM To Cano

The Yankees will not offer star free agent second baseman Robinson Cano a deal for over $200MM, reports Jeff Passan of Yahoo Sports. With a current offer of seven years and $160MM already on the table, the club plans to stand on that figure and does not foresee wiggle room of greater than about $15MM, says Passan.

As Passan goes on to explain, the major question hanging over negotiations is whether any other clubs will jump in at or above the current Yankee offer. He mentions the Nationals and Mariners as the two teams most likely to jump in as serious bidders for Cano. 

New York could be exerting pressure on Cano by beginning its spending and pursuing other free agents like Jacoby Ellsbury and Shin-Soo Choo. Ultimately, says Passan, "unless something drastic happens" the club will not sign Cano for anything approaching his current demands.

Olney On Starters, Mariners, Anderson, Mets, Rockies

As we continue to work our way through what has been a slow holiday weekend, here are a few interesting notes from ESPN.com's Buster Olney:

  • Starting pitching demand may not be sufficient to drive up the salaries of Ervin Santana, Ubaldo Jimenez, and Matt Garza, argues Olney. Each member of that trio is rumored to be seeking a major, long-term deal. But as Olney observes, several factors — including the wait for Masahiro Tanaka, possible trade availability of some major arms, and imperfect track record of all three hurlers — could conspire to limit their market.
  • One team that "seems bound" to land one of that threesome, according to Olney (via Twitter), is the Mariners
  • Ticking through each team in baseball to gauge possible interest in one of these upper-middle-class starters, Olney includes a few interesting notes on some clubs. For instance, Olney twice notes that the Athletics' Brett Anderson is available via trade and could well be dealt if Oakland brings back Bartolo Colon or another short-term starter. He has previously reported that the Royals might be interested in buying low on Anderson.
  • The Mets, meanwhile, "have been looking more at second-tier and third-tier free agents." That fits the most recent rumors out of New York, though it is sure to disappoint those who expect the club to ink at least one major free agent. As I discussed in my offseason outlook for the Mets, the club has professed to have $40MM in payroll space for next year, and so far has committed less than a fifth of that by signing Chris Young.
  • Likewise, according to Olney, the Rockies are putting out word that they do not have a lot to spend in free agency. Of course, the club reportedly made legitimate runs at both Jose Dariel Abreu and Brian McCann, though it could be that it was only willing to spend big on certain players.

MLB And MLBPA Release 2013 Report On PED Testing

Yesterday, MLB and the MLB Player's Association released the 2013 public report on the Joint Drug Prevention and Treatment Program (commonly referred to as the JDA). The report was compiled by Dr. Jeffrey M. Anderson, the Independent Program Administrator.

The report addresses drug testing over the period between the start of the 2012-13 off-season and the end of the 2013 post-season. A total of 5,391 drug tests were conducted, 4,022 of which were urine samples analyzed for PEDs and/or stimulants. The remaining 1,369 instances were blood samples tested for human growth hormone (hGH).

Of the samples analyzed, eight resulted in "an adverse analytical finding that resulted in discipline," all of which were for the stimulants Adderall or Methylhexaneamine. The report also notes thirteen "non-analytical positives" that resulted in discipline. In addition, the league granted 122 therapeutic use exemptions, the vast majority of which were for Attention Deficit Disorder.

Comparison to last year's report shows marginal increases in overall testing numbers. In 2012, there were 5,136 samples taken, 3,955 of which were urine tests and 1,181 of which were for blood. That means that, along with 67 more of the former, there were an additional 188 instances of blood testing this time around. Therapeutic use exemptions remained relatively constant. The most interesting fact, perhaps, is that no positive PED tests were identified, down from seven last year. Instead, this time around, we saw the thirteen suspensions based upon Biogenesis-related investigation rather than testing. 

Of course, the JDA provides careful parameters for testing. Every player is subject to a urine test upon reporting to Spring Training and is subject to an additional random urine test at some point between the commencement of Spring Training and the end of the championship season (i.e., the conclusion of the regular season). The JDA allows 1,400 additional random tests, 200 of which were allowed to be performed during the off-season in the 2012-13 testing period. As for blood testing for hGH, every player must provide a sample at an unannounced point during Spring Training and a sample can also be taken in conjunction with an off-season urine test. The JDA also provides for further testing based upon reasonable cause as well as follow-up testing for disciplined players.

In large part, of course, the figures released yesterday confirm that the testing program took the form that the JDA contemplated. Last year, about 4.5 tests were performed for each of MLB's 1,200 available roster spots. (Of course, roster spots aren't always all full, and a good number of players cycle through them in a given season.)

But a good portion of the testing is not truly unpredictable, as it takes place at the start of or during the six-week Spring Training period. Assuming that the MLB testing figures reflect a relatively low number of reasonable cause and follow-up tests, something in the vicinity of 3,000 tests were essentially random. With about 320 non-Spring Training days on which those tests could theoretically have fallen, and 1,200 MLB roster spots available on a given day, the percentage of "player-days" that see some kind of surprise PED test is a comfortable bit less than 1%. 

Depending upon how baseball plans to implement and report its in-season hGH testing program, those testing rates stand to remain essentially constant through the life of the current JDA, which expires on December 1, 2016. So, is that sufficient, at least for the time being? 

As MLB COO Rob Manfred has explained, the frequency and randomness of testing is critical. Discussing minor league testing back in 2010, he said: 

"We not only incrased the number of tests conducted this year in the [Dominican Republic], but significantly altered the pattern of testing. And, whenever we do that, we get a spike. Major League, Minor League, in the DR, whenever we change the pattern so that it's not predictable, we get a spike."  

These old-but-illuminating comments are especially interesting in light of the fact that the testing system registered no PED hits this season after logging seven in 2012. It would seem naive to assume that the shift reflects a sudden and drastic reduction in PED use. But if it instead constitutes a step back for testing efficacy, what is the solution? Unless a numerical increase in tests can be negotiated, Manfred's past statement indicates that the league may need to get creative with its process to ensure that baseball's PED testing protocol adequately supports its disincentive system.

AL East Notes: Cano, Orioles, Drew

Robinson Cano denied asking the Yankees for a $300MM deal back in the summer, writes Andy Martino of the New York Daily News, but just because Cano didn't utter the words himself does not mean that his representatives did not float that number. That was just the "midseason request," however, Martino explains. Now that the star second baseman has reached the open market, his camp has re-set its asking price and is scheduled to meet with the Bronx brass again on Monday. Here's more from the American League East:

  • The Orioles are quietly waiting for the free agent starting pitching market to fall into place, writes Eduardo Encina of the Baltimore Sun. We've heard before that the club is quite interested in returning Scott Feldman, who was acquired in mid-year from the Cubs, and Encina guesses he'll take two years and $16-18MM to land. In his detailed breakdown of Feldman, MLBTR's Steve Adams projected his value at two years and $17MM, plus a vesting option. Other arms that might draw attention from Baltimore, according to Encina, are Bronson Arroyo and even A.J. Burnett, if he decides to look around the market. 
  • Shortstop Stephen Drew is still a great fit for a Red Sox infield that currently features Xander Bogaerts and Will Middlebrooks on the left side, writes John Tomase of the Boston Herald. If Drew can't get a club to give up a pick to sign him to a multi-year deal, Boston could swoop back into the mix and try to land him on another one-year contract, perhaps with an implicit promise not to extend another qualifying offer, Tomase suggests.

Pitching Notes: Dodgers, Giants, Mujica, Ayala, Williams

The market for starting pitchers has actually started off at reasonable prices, argues Mike Axisa of CBSSports.com. Running the numbers on the price of a projected win for the starters who have signed to date, he says that a preliminary look shows that early-moving teams look to have achieved solid value. Here's more on the pitching market around the league:

  • Even if the Dodgers are willing to spend the huge amount of cash that Masahiro Tanaka's posting and signing is expected to require, says Mark Saxon of ESPNLosAngeles.com, it is far from clear how the club would sort its rotation out to accomodate him. GM Ned Colletti has said that he is "not going to close the door on any more starters" even after adding Dan Haren on a one-year deal with a vesting option. Saxon notes, however, that it would be more difficult to push aside Josh Beckett and/or Chad Billingsley than it was for the club to do last year with Chris Capuano and Aaron Harang. Of course, Tanaka may be good enough that, if the price is right, that problem is one you just deal with as best you can.
  • The Giants, on the other hand, seem less likely than their rivals to the south to consider the addition of another starter, with Bob Nightengale of USA Today reporting that the club's rotation is set after re-signing Ryan Vogelsong. As Alex Pavlovic of the Mercury News noted earlier today, the rotation seemed complete upon the return of Vogelsong, given GM Brian Sabean's earlier comments that he would not make the veteran compete for his slot in the spring. Matt Cain, Madison Bumgarner, Tim Lincecum, and Tim Hudson round out the club's starting five.
  • Meanwhile, it could well be that San Francisco could look to add pen pieces given their decision to add veteran arms to the back of its rotation, reasons Henry Schulman of the San Francisco Chronicle (via Sulia). It is easier and cheaper to add relief arms, he notes, and the club could look to ease the burden on its starters by following the Dodgers and Cardinals in trotting out multiple arms that can throw quality innings.
  • Free agent reliever Edward Mujica of the Cardinals is drawing interest from a variety of teams, according to Chris Cotillo of MLBDailyDish.com. The Angels are probably out after inking Joe Smith, Cotillo notes. But the OriolesIndians, and Cubs have at least kicked the tires on Mujica, joining the Phillies in pursuit of the 29-year-old. 
  • Right-handed reliever Luis Ayala, who produced solid results last year at age 35 for the Orioles and Braves, is also in search of a multi-year deal, Cotillo reports. He has not yet seen an offer, but has received interest from the Red Sox and Rays as well as the Dodgers, Giants, O's, and Phils. Meanwhile, the Royals have seemingly stepped away from Ayala after showing initial interest.
  • One other arm that could enter the market is Angels righty Jerome Williams. Soon to turn 32, Williams' agent Larry O'Brien tells Cotillo (Twitter link) that he is rooting against a tender from the Halos since "there are many teams he could effectively start for." That statement seems to imply what has long been suspected about Williams, which is that Los Angeles does not intend to use him as a starter. As MLBTR's Tim Dierkes wrote in reporting Matt Swartz's $3.9MM projection for Williams, a non-tender is a very real possibility for the swingman. Of course, as MLBTR's Zach Links has explained, there are few teams with as many projected rotation holes as the Angels.

Dodgers Discussing Extension With Hanley Ramirez

Hanley Ramirez said recently that he has had ongoing extension talks with the Dodgers, Dionisio Soldevila of ESPNDeportes.com reports (Spanish language link). The 29-year-old is under contract for next year, but his impressive output in an injury-shortened 2013 makes him a definite extension target for Los Angeles. 

Reiterating once again that he hopes to stay with the Dodgers for the rest of his career, Ramirez said that he believes a new deal could be reached this winter. "We are negotiating something, but we are going step by step," he said (in Spanish). Ramirez declined to discuss the salary and length under consideration, but it is safe to say that the shortstop/third baseman is in line for quite a substantial contract when his current six-year, $70MM pact expires.

Last year, in 336 plate appearances, Ramirez posted an outstanding .345/.402/.638 slash, including twenty home runs and ten stolen bases. His 191 wRC+ landed just behind Miguel Cabrera among players with triple-digit plate appearances. In sum, his half-season of work was good for 5.1 fWAR, 25th among field players in all of baseball. 

Peralta, PED Incentives, And The Next JDA

We've all seen the range of responses to the four-year, $53MM deal that Jhonny Peralta inked with the Cardinals right on the heels of serving a fifty game suspension for violating the performance enhancing substances prohibitions contained in the league's Joint Drug Prevention and Treatment Program (JDA). Rather than rehash them here, or take a moral stand in one way or another, I'd like to look at things from a practical perspective.

By guaranteeing four years at over $13MM per, the contract went well beyond the biggest multi-year deals given to other players recently hit with a suspension just before hitting free agency. That doesn't change the moral calculus, but it does highlight that — as MLBTR's Steve Adams has explained — teams may not be substantially reducing their valuation of a player based on his past usage of PEDs. Though clubs may factor in some negative PR value, discount past performance during periods of use, or add in a bit of an additional risk adjustment, the net just isn't that great.

Peralta may well have landed his deal because of his steady production and defense at a position in great demand on the present market, rather than his PED use. But he just as surely did not lose his deal because of the banned substances that he took.

This matters most, it seems to me, because of what it says about incentives. Teams' market-driven decision-making is apparently not going to provide a significant disincentive on its own. And the fact is, as Cards' GM John Mozeliak correctly points out"at this point in the game, there's nothing that says [Peralta] can't go play or isn't free to go sign with another club."

And, arguably, neither is the JDA itself doing enough to shift the PED equation. Like all punitive systems, the JDA sets up upon negatives incentives to outweigh positive incentives to engage in the behavior it wishes to prohibit. As Diamondbacks reliever and union rep Brad Ziegler said on Twitter: "We thought 50 games would be a deterrent. Obviously it's not." 

This may be somewhat overstated: the shaming effect (especially given the shift in player sentiment) and suspension process seem to be having at least some effect, as most observers acknowledge that PED usage is not nearly as rampant as it once was. On the other hand, Ziegler is definitely on to something. At least for some players, in some situations, the benefits to using PEDs outweigh the drawbacks — even, perhaps, if they are caught. The meager weight of the current suspension system, I think, is the most worrying lesson from the Peralta deal. 

Viewed in its worst light, the suspension system creates a mental process much like the kitchen table scene in Office Space. Playing the devil on the shoulder of his would-be co-conspirators, Peter Gibbons seals their agreement to skim cash from their hated employer by dismissing the downside: "This isn't Riyadh. … The worst they would ever do is they would put you for a couple of months into a white-collar, minimum-security resort!"

But is it really the case that the use of banned substances could, in some cases, present only de minimus downside for a player? Is Ziegler right that Peralta shows that "it pays to cheat"

In some ways, that certainly could be the case. Players who get caught with their hand in the cookie jar often claim they used PEDs to help recover from injury, not to artificially boost performance. Now that we're past the era of cartoonishly outsized sluggers, that may even be the most common and impactful use of PEDs. You know, just getting back to a player's regular level of production and giving him a chance to demonstrate his value at an opportune time. Sure, he may pay for it later by giving up fifty games worth of salary. But the chance to, say, highlight performance before hitting free agency, or jump at an early-career MLB opportunity, can often be invaluable to a ballplayer. 

So, assuming that a blanket ban on the list of disallowed PEDs is in fact the goal — putting aside, in other words, the debate on their use in injury rehab — it seems to me that a more thoughtful disincentive system is plainly needed. As a baseline, it is important to recognize that PED prohibition is an agreed-upon rule of the game, and its enforcement is as much about fairness to clean players (and to fans) as it is about keeping dirty players from using to their own long-term health detriment.  

Click below to see my conceptual proposal for some methods that might be employed, individually or in concert, to arrive at a more effective system of PED disincentives. These include: eliminating suspensions altogether; varying punishment based upon service time and/or contract status; and utilizing financial disincentives while minimizing impact on competition and the market.

Read more

Giants Nearing One-Year Deal With Ryan Vogelsong

5:23pm: The Giants are offering "north of $3MM for sure" in guaranteed money to Vogelsong, Schulman reports, and roughly $4MM in total.  Signing Vogelsong would mean the Giants would (at least for now) turn away from signing another starting pitcher to a multiyear deal and instead focus on finding a left fielder.  Also from Schulman (Twitter link), the Giants were still interested in Bronson Arroyo as of this morning, though it's unclear how signing Vogelsong could affect their pursuit of Arroyo.

TODAY, 12:41pm: The club is nearing a one-year pact with Vogelsong, reports MLB.com's Chris Haft, with "momentum" gathering toward an agreement. Vogelsong reportedly wants incentives that could boost the contract value into the $7-$8MM range, while the Giants have indicated that they'd be amenable to bringing him back on a deal that combines base salary and incentives to reach or exceed the value of the option that the club declined. Of course, given that San Francisco decided against promising Vogelsong $6.5MM, it seems clear that the guaranteed portion of a new deal would fall shy of that figure.

YESTERDAY: The Giants are moving toward a deal with free agent starter Ryan Vogelsong, tweets Henry Schulman of the San Francisco Chronicle. San Francisco recently declined a $6.5MM club option on the 36-year-old righty.

Vogelsong, a client of Dave Meier, was a minor league deal reclamation project for San Fran who turned in two outstanding seasons over 2011-12. He suffered an injury-aided downturn last year, however, posting a 5.73 ERA in 103 2/3 innings. Vogelsong registered a notably lower 5.8 K/9 rate in 2013 and saw his HR/FB leap to 13.4%. While advanced metrics put a better light on his campaign, his 4.91 FIP and 4.50 xFIP were hardly promising.